Therefore, in our study, we conducted a detailed investigation into the three drug targets of metformin (ETFDH, GPD2, and PRKAB1), and the discovery cohorts and integrated results revealed that GPD2 has an inhibitory effect on the occurrence of rectum cancer. Here, ETFDH is linked to rectal cancer.